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The purpose of this research is to identify and explore effective supply chain 
management principles as mitigating measures to improve contingency pharmaceutical 
item shortfalls in the Air Force Medical Service Contingency Pharmaceutical Program. 
Analysis of current pharmaceutical shortages demonstrates a significant trend of 
insufficient demand signals for various pharmaceutical items, resulting in instances of 
non-fulfillment by private sector suppliers.  
Through the scope of transaction cost economics, a cost-benefit analysis for 
various alternatives was conducted. The proposed alternatives evaluated in this thesis 
include continuation of the status quo, centralized procurement models from a single site, 
and procurement from regionally designated ordering sites. 
This research clearly shows that consolidating demand of shortage items across 
Active Duty War Reserve Material assemblages, though applications of centralized 
purchasing principles that leverage prime vendor contract fill rates, can lead to substantial 
increases in material availability at costs that justify the calculated benefits. 
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STRATEGIC SOURCING OF AIR FORCE CONTINGENCY 
PHARMACEUTICALS: A COST-BENEFIT ANALYSIS APPROACH 
I. Introduction
Background 
Forecasts for the year 2020 project that supply chain expenses will become the 
largest expenditure for U.S. healthcare organizations, commanding more budgetary 
requirements than the previous top expense of labor (Paavola, 2019). This means that the 
materials which allow a healthcare facility to function could now attract more attention 
than the medical professionals who provide the actual service of healthcare. At the same 
time, organizations are experiencing increasing costs across the entire spectrum of 
healthcare provision which are further cutting into profit margins (Paavola, 2019). In a 
strategic effort to increase performance outcomes, organizations are shifting focus to the 
improvement of supply chain management as an efficiency driver. This information has 
healthcare leaders focusing on practices and policies to extract value and minimize waste 
from supply chain practices. Practices such as demand aggregation through group 
purchase organizations, efficient data processing and analysis, and item standardization 
have garnered attention of the biggest healthcare companies in the country in an effort to 
improve supply chain operations (Michigan State University, 2019).  
This research takes the strategic supply chain focus found in the private sector, 
and applies lessons learned to make Air Force Medical Service (AFMS) operations more 
effective. Therefore, the purpose of this research is to identify, evaluate, and apply 
optimal supply chain efforts to address shortages in the Air Force Contingency 
Pharmaceutical Program. Analysis of current contingency pharmaceutical shortages 
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shows a significant trend of insufficient, individual site demand signals for various 
pharmaceutical items, resulting in non-fulfillment by private sector suppliers. This 
research applies a cost-benefit analysis to evaluate various alternatives through the 
theoretical scope of transaction cost economics. As a result, this research clearly shows 
that consolidating the demand of shortage items across Active Duty War Reserve 
Material (AD WRM) assemblages, though applications of centralized purchasing 
principles that leverage prime vendor contract fill rates, can lead to substantial increases 
in material availability for pharmaceutical items. 
The AFMS currently manages a $1.3 billion contingency medical program 
comprised of over 5,100 assemblages across the globe at 87 unique locations (JMAR, 
2019). According to the Air Force Medical Logistics Guide, this program supports the 
capabilities of medical units in contingency situations such as home station medical 
response, deployments, and humanitarian efforts (AFMOA/SGAL, 2017). A critical 
element of contingency medical assemblages are pharmaceutical items, which account 
for over $113 million of the program (JMAR, 2019). A crucial subset of the overarching 
contingency medical program, and a primary focus of this research, are AD WRM 
assemblages. These assemblages are durable and transportable kits that provide necessary 
medical items, including medical supplies, equipment, and pharmaceuticals to  
accomplish deployment or mobility objectives (AFMOA/SGAL, 2017). Pharmaceutical 
items, as a component of AD WRM assemblages, experience high turnover due to 
consumption or expiration, as items routinely have a shelf life of only 24 to 36 months 
(AFMRA MLD, 2019). As a result from an enterprise-level, the Air Force Medical 
Readiness Agency (AFMRA), Medical Logistics Readiness Support Branch, has 
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observed shortages in material availability for many of these pharmaceutical items 
(AFMRA MLD, 2019).  
Problem Statement 
Over 35 percent of all Air Force contingency medical assemblages, and 21 
percent of AD WRM material assemblages, do not meet deployment requirement 
thresholds as defined by AFMAN 41-209 (JMAR, 2019). Deployment thresholds 
according to this guidance require a minimum of 90 percent material availability of 
commodity items contained in the assemblage (U.S. Air Force, 2019). A major driver of 
this shortfall is the inability to readily procure contingency pharmaceutical items, which 
account for 41 percent of all contingency item shortages across the entire contingency 
pharmaceutical program (JMAR, 2019). Due to the unpredictable nature of contingency 
operations many contingency pharmaceutical items have non-recurring or non-usage 
demands, compared to Medical Treatment Facility (MTF) day-to-day pharmaceutical 
demands which have established and frequent usage patterns that result from supporting a 
relatively predictable healthcare environment (AFRMA MLD, 2019). This ambiguity in 
demand leads to order rejections for contingency items as Department of Defense (DoD) 
contracted distributors are only obligated to fulfill items which have established usage 
demands (Defense Logistics Agency, 2013).  
This contractual condition leaves the AFMS at a disadvantage in developing and 
maintaining adequate inventories to support current and future requirements, which could 
occur with the onset of contingency operations. According to the 2016 Defense Logistics 
Agency (DLA) Medical Supply Chain report, DoD pharmaceutical item purchases 
4 
through DLA Troop Support make up only 1 percent of the entire U.S. pharmaceutical 
industries’ market share (Defense Logistics Agency, 2016). For this reason, the Air 
Force, as a DoD component, must ensure that demand signals for contingency items are 
as robust as possible to ensure adequate supply for required inventories. Ultimately, 
inefficiencies and shortfalls of contingency item supply chains could directly impact our 
Nations’ readiness in military and humanitarian operations.  
Purpose Statement 
The purpose and primary goal of this analysis is to identify and explore effective 
supply chain principles, through the theory of transaction cost economics, as mitigation 
measures to improve current contingency pharmaceutical item shortfalls in the AFMS 
program. Through these approaches the resulting analysis will inform leaders about 
possible mitigation efforts, and their inherent costs and benefits, in an effort to remedy 
shortfalls in contingency pharmaceutical procurement methods.   
Research Questions 
RQ 1: Are there strategic supply chain integration efforts that can be employed to remedy 
current shortfalls? 
RQ 2: What are the costs and benefits of possible strategic supply chain integration 
efforts? 
Research Focus 
First, the theoretical scope of transaction cost economics is reviewed to build the 
research foundation to conduct an assessment of contingency item procurement 
processes. The literature review also evaluates current contingency medical procurement 
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processes, introduces the concept of cost-benefit analysis, and highlights principles of 
strategic sourcing and demand aggregation. Subsequently, the data collection practices of 
this research and methodological applications of cost-benefit analyses are outlined. 
Lastly, findings are presented with a discussion on research limitations and areas for 
future research. 
Methodology 
The methodology utilized to gather information and present the findings of this 
research is a cost-benefit analysis. The cost-benefit analysis conducted in this thesis was 
influenced by the framework outlined in the text, Cost-Benefit Analysis: Concepts and 
Practice. 
Assumptions 
The main assumption of this thesis is that the AFMS will maximize use of the 
established DLA Pharmaceutical Prime Vendor (PPV) contracts to the fullest extent 
possible to procure needed contingency items. Demand, in terms of this research will be 
the current contingency pharmaceutical item shortages for each location. The DLA PPV 
contract defines a usage item as a pharmaceutical that is, “ordered by the ordering facility 
a minimum of once per month for a minimum quantity of one and is in the Medical 
Master Catalog (MMC). Usage data shall be provided by the customer during the 
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implementation period and will be reviewed by the customer and the PPV periodically” 
(Defense Logistics Agency, 2013, p. 41).  
This thesis also applies the fact that all Air Force ordering stock record ordering 
locations are designated as Master Ordering Facilities (MOFs) under the PPV contract. 
These MOFs are authorized to order under the PPV contract for external DoD customers 
(Defense Logistics Agency, 2013). With this designation applied to AFMS ordering 
units, the centralized and regionalized ordering facilities, identified in the constructed 
alternatives, can set up delivery locations at external sites, given they are in the same 
geographical region (Defense Logistics Agency, 2013). This effort would minimize 
transportation expenses as there are no distribution fees for all MOF orders according to 
the PPV contract (Defense Logistics Agency, 2013). Lastly, ordering sites located in the 
Upper Prairie region will fall under the West region for demand aggregation, ordering, 
and resulting distribution of shortage items due to their proximity to the West region. 
Limitations 
The scope of this research focused specifically on the 120 AD WRM deployable 
unit type code allowance standards, shown in Appendix A. Therefore, the programs of 
Home Station Medical Response (HSMR), Force Health Protection (FHP), Mass 
Casualty First Aid Kits, and MAJCOM specific programs were not evaluated in this 
research. Also, this research did not include and in-depth evaluation or shortage 
remediation of non-pharmaceutical contingency items, including contingency medical 
equipment, repair, or supply items. Lastly, other military services’ contingency 
pharmaceutical items, ordering policies, or budgetary information was not assessed in 
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this evaluation. These separate contingency commodity items and other service 



















II. Literature Review 
Chapter Overview 
The purpose of this chapter is to provide the foundational knowledge used to support 
the decision of aggregating demand for shortage items across the enterprise in an effort to 
implement centralized procurement practices. This chapter begins with an evaluation of 
transaction cost economics theory. This topic will provide the theoretical foundation for 
the assessment of contingency item procurement purchasing processes.  
This literature review will then highlight the various policies and regulations that 
form and govern the current processes in AFMS contingency item procurement. Through 
review of these methods, a concise and consolidated process will be outlined from the 
planning stage to the execution phase. This chapter also introduces the concepts and 
outlines the steps of a cost-benefit analysis. Lastly, supply chain principles of strategic 
sourcing are fully evaluated. The strategic sourcing component applied in this thesis is 
the concept of implementing centralized purchasing structures through practice of 
demand and purchasing aggregation to establish sufficient usage data for contingency 
pharmaceutical items.  
Transaction Cost Economics 
The review of applicable literature and theory for this research begins with a 
description of transaction cost economics. The basic premise of transaction cost 
economics theory instantiates that individuals or firms seek to make the best possible 
decisions for their organization. This theory holds that organizations select certain 
products, goods, or services over alternatives due to the economization, optimization, or 
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minimization of transaction costs (Williamson, 1979). In transaction cost economics 
theory, the unit of analysis is the singular transaction (Williamson, 2010). A transaction 
in this theory is defined as an economic exchange of a good or service from a provider to 
a separate user (Pint and Baldwin, 1997). Transaction costs can arise from a litany of 
organizational functions and actions, including sourcing selections, contract management, 
and performance measurements (Pint and Baldwin, 1997).  
Since organizations usually operate in resource-constrained environments, it is 
paramount that they make economically efficient decisions in charting future financial 
and operational decisions (Mahoney and Ketokivi, 2015). As the AFMS is not immune to 
this prevalence of constrained operating environments, their business practices are highly 
suitable for evaluation through a scope of transaction cost economics. Limited budgets, 
constraints on contracting and purchasing avenues, and the unpredictable nature of 
military operations fuel the often constrained environment of Air Force procurement. 
These decisions in constrained environments can range from organizational structure 
constructs, personnel configuration, or purchasing efforts; however, all focus on a key 
idea of managing relationships and transactions to minimize waste while simultaneously 
creating value (Mahoney and Ketokivi, 2015).  
Throughout the evaluation of transaction cost economics, the theme of bounded 
rationality emerges as a key concept. Bounded rationality implies that there are limits to 
time, control, and information throughout a system, which can result in suboptimal 
decisions, actions, and organizational principles (Pint and Baldwin, 1997). This means 
that entities of the system, including employees, processes, and agreements, may engage 
in or promote suboptimal behavior, that can be detrimental to effective decision making 
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in operations (Pint and Baldwin, 1997). Bounded rationality is not a result of 
incompetence or inability, but rather a product of the fact that humans have limitations 
that influence actions and strategy (Williamson, 2010). Williamson (2010) describes that 
humans are limited in their rationality due to complexities found in the business 
environment. Transaction cost economics suggests that when the resulting effects of 
bounded rationality greatly influence organizational transactions, organizational 
integration efforts could be used to ensure the value of transactions are captured (Pint and 
Baldwin, 1997). This concept of integration, through the implementation of centralized 
procurement procedures, will be further evaluated in this literature review. 
Contingency Item Purchasing Processes and Shortfalls 
There are undoubtedly various transaction costs associated with the procurement 
of contingency pharmaceuticals, but before the minimization of these costs and 
maximization of value can be pursued, the initial processes of contingency item demand, 
outlined in Appendix B, must be evaluated. The initial step of the planning process 
begins at the operational planning (OPLAN) level where Combatant Commanders’ 
capability requirements for medical assets are defined and transferred to the Air Force 
Surgeon General’s (AF/SG) Office (HQ USAF/SG, 2013). These resulting OPLANs lay 
out requirements for medical necessities in contingency instances such as number and 
types of beds based on projected casualty streams, number of personnel deployed in the 
area and aeromedical evacuation projections (AFMRA/SG4M, 2019). From these 
OPLAN requirements, the AF/SG publishes the Medical Planning and Programing 
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Guidance (MPPG) to determine future endeavors in contingency planning (HQ 
USAF/SG, 2013). 
The MPPG, as the Air Force Medical community’s planning and programming 
guidance document, ultimately determines the bottom up requirements to support medical 
program priorities, such as WRM, in support of combatant commander requirements (HQ 
USAF/SG, 2013). The process for putting the AF/SG vision, as outlined by the MPPG, 
into action is the Readiness Requirements Planning and Resourcing Process (RRPR). In 
the RRPR medical unit type code requirements are identified for these major OPLANs, 
which creates the total demand list (TDL) (HQ USAF/SG, 2013). The TDL is the 
resulting product of the RRPR that captures all combatant commander requirements, thus 
establishing the demand for the system (HQ USAF/SG, 2013). The establishment of the 
TDL, from the origins of the various OPLANs, concludes the planning phase of 
contingency item procurement. Execution of this process begins with the Medical 
Requirements List (MRL).  
The MRL is a conglomeration of all AFMS possible personnel and equipment 
assignments, mission requirements, and expansion capabilities (HQ USAF/SG, 2013). 
Ultimately, this listing outlines where each required capability, as defined by the TDL, 
will be stationed and in what fiscal year the capability will be required (HQ USAF/SG, 
2013). Once requirements are distributed amongst Air Force locations, via the MRL, 
assemblages are constructed, supported, and replenished at dictated sites through 
established procurement channels, including the Pharmaceutical Prime Vendor (PPV) 
contract.  
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The PPV contract, awarded through DLA, is the primary mechanism exercised for 
procuring contingency pharmaceutical items. The contract was awarded in 2014 and 
consists of one 30 month base period and three 30 month option periods, available 
through 2024 (Defense Logistics Agency Troop Support, 2019). In Fiscal Year (FY) 19, 
the breakdown of contingency pharmaceutical purchases shows utilization of the PPV 
contract over 70 percent of the time in pharmaceutical procurement actions (JMAR, 
2019). According to DLA, fulfillment rates for the PPV contract typically range from 95-
98 percent (Defense Logistics Agency Troop Support, 2019). This generalization was 
substantiated by obtaining access to information from the fill rate module managed by 
DLA. The average fill rate for the FY19 was 96.19 percent (“Fill Rate Application”, 
2019).  
This fill rate percentage will be used as a factor in the cost-benefit analysis 
methodology to calculate remedied shortage amounts. According to the contract 
statement of work, “The PPV program provides worldwide support to DoD customers 
[…] by providing pharmaceutical and pharmaceutical related products. The PPV will 
provide War Readiness Material (WRM) support” (Defense Logistics Agency, 2013, p. 
31). After solicitation, the contract was awarded to Amerisource Bergin Drug 
Corporation (ABC), designating them as the primary supplier of pharmaceutical 
contingency items to the DoD (Defense Logistics Agency Troop Support, 2019). ABC 
services both CONUS and OCONUS contingency pharmaceutical demands from its 
nearly 30 U.S. distribution centers (Amerisource Bergin, 2015). All geographical regions 
are serviced by ABC, with the exception of the states of South Dakota, North Dakota, and 
Minnesota. These states are serviced by the Dakota Drug Company under the designation 
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of the Upper Prairie Region through a separately awarded small business contract 
(Defense Logistics Agency Support, 2019).  
Under the current contract, the primary supplier must maintain a fill rate of 98 
percent for all orders predicated upon sufficient usage demands (Defense Logistics 
Agency, 2013). This distinction is highly important, as it identifies that the fill rate will 
only be inclusive of products which meet usage requirements. Usage under the contract is 
defined as an item, “ordered by the ordering facility a minimum of once per month for a 
minimum quantity of one and is in the Medical Master Catalog (MMC). Usage data shall 
be provided by the customer” (Defense Logistics Agency, 2013, p. 40). With the 
shortcomings discussed above through the PPV contracts, it is clear that additional 
mitigating measures must be evaluated to address current system issues. 
Cost-benefit Analysis 
A cost-benefit analysis is a methodology for accurately assessing policies or projects 
based on their associated impacts, in terms of benefits and costs, that are valued in 
monetary terms (Boardman, Greenberg, Vining, and Weimer, 2011). Cost-benefit 
analyses are a common evaluation tool in military environments used to shape national 
security, set acquisition policies, and direct investments in service and supply 
procurement (Melese, Richter, and Soloman, 2015). According to Boardman et al. 
(2011), there are three types of cost-benefit analyses, including ex-ante, in medias res, 
and ex-post. Ex-ante analyses evaluate new initiatives that could possibly be 
implemented in the future (Boardman et al., 2011). In medias res analyses are actually 
conducted during the life of a current project, while ex-post analyses are completed after 
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a project has been completed or retired (Boardman et al., 2011). The current contingency 
pharmaceutical procurement program, supported primarily through the DLA PPV 
contract, will be analyzed through an in medias res cost-benefit analysis as the contract is 
still valid with options for continuation through 2024 (Defense Logistics Agency, 2013). 
In looking outside of the scope of current contracting vehicles, the findings of this cost-
benefit analysis could also provide useful insight for future solicitations of DoD 
contingency item contracts.  
An in medias res cost-benefit analysis can be accomplished through navigation of the 
following steps: specification of alternative projects, identification of project 
stakeholders, determination of costs and benefits, quantitative prediction of impacts over 
the life of the project, monetization of impacts, discounting of benefits to obtain present 
values, computation of the present value of each alternative, sensitivity analysis, and 
crafting of final recommendations (Boardman et al., 2011). For the purposes of this 
research, as the data provided encompasses single year contingency pharmaceutical 
procurement values, the steps of monetization of impacts, discounting of benefits to 
obtain present values, and computation of the final present values will be compressed into 
a single step designated as monetization. The resulting steps are illustrated below and will 
be used as this research’s methodological framework to evaluate and compare alternative 
actions. 














The first step of the cost-benefit analysis is to clearly identify all possible options that 
could be undertaken in the given environment. In this first step of identifying alternative 
projects, the wide array of possible options must be defined and limited, as in most cases, 
there are a large number of viable options (Boardman et al. 2011). Within this set of 
alternatives, the current status quo, or instance of no change, should also be fully 
evaluated. Status quo information is needed to compare the current project to 
hypothesized options to determine if a new course of action, with its associated costs and 
efforts, should even be attempted (Boardman et al., 2011). In the methodology section, 
the status quo and possible alternative actions, with varying applications of centralized 
procurement, are defined. 
Following the definition of alternatives stakeholders need to be properly identified. 
Identification of these stakeholders can be difficult to delineate and scope down to a 
relevant level for the given analysis being undertaken (Boardman et al., 2011). Projects 
can often be analyzed from a focused level excluding higher level or external 
stakeholders who may have a more global perspective (Boardman et al., 2011). 
Therefore, it is critical to evaluate possible stakeholders fully and then scope based on the 
level of connection to the project. In the AFMS contingency procurement model, certain 
benefits, as well as costs, could be felt at a local base level; however, there are likely 
additional costs and benefits that are realized at the enterprise level. Once all relevant 
stakeholders of the project are identified and informed, the costs and benefits of the 
project must be evaluated.  
Evaluating the costs and benefits of a project are first done by identifying the physical 
impact categories of the possible alternatives (Boardman et al., 2011). The term impacts 
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include the inputs and outputs of a project, which are then cataloged as either a cost or a 
benefit to the project (Boardman et al., 2011). Boardman et al. (2011) provides a 
framework of identifying a cause and effect relationship between physical outcomes of 
the project and the affected parties. If there is a correlation between stakeholder action 
and outcome of the system, there is likely an impact category that can be identified as a 
benefit or a cost (Boardman et al., 2011). These resulting benefits and costs then need to 
be measured in some form of units. The method for measuring each impact is usually 
based upon the data from which the project is evaluated (Boardman et al., 2011). This 
means if there is monetary information, the resulting impacts will likely be measured in 
increased profit or cost avoidance; however, there are many ways that impacts can be 
measured, including time savings or operational efficiency improvements (Boardman et 
al. 2011).  
After impacts have been identified, the task is to then predict the impacts over the life 
of the project (Boardman et al., 2011). Based on the calculated costs and benefits, the 
analyst needs to tie the impacts to a quantifiable output. The purpose of a cost-benefit 
analysis is to assess alternative courses of action which require prediction of outcomes 
supported by accurate data  (Boardman et al., 2011). The methodology section of this 
research will apply data analysis of current information to predict impacts of different 
project implementations. Benefits resulting from changing processes, compared to 
current operations, can be analyzed through the in media res cost-benefit analysis. 
Once cost and benefit predictions are established, it is important to assign monetary 
values in order to effectively compare outcomes as options may have differing costs and 
benefits that cannot be compared on a direct unit level. Effectively monetizing values can 
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allow for interpretation and comparison of results as it gives differing impacts similar 
units (Boardman et al., 2011). In some cases it is relatively simple to apply a monetary 
value to an impact, such as instances of cost avoidance; however, in many occurrences 
these monetary evaluations are not easily constructed. This is especially true in the 
military or defense environment.  
In these instances where monetization is not straight forward, Boardman et al. (2011) 
advocates for avoiding reinvention of established practices through the use of plug in or 
estimated values when available. There is no silver bullet in connecting resulting outputs, 
such as increased material availability, with quantitative, economic inputs, such as money 
spent. However, a mechanism for quantifying the resulting impacts in military or defense 
situations is proposed in the military production function, which attempts to quantify 
defense outputs based on monetary inputs (Hartley and Soloman, 2015). According to 
Hartley and Soloman (2015) “Defense outputs involve a complex set of variables 
concerned with security, protection and risk management […] unlike private markets 
there are no precise benefit measures for defense output” (p. 44). Inputs, such as cost of 
procurement, are more easily identified and measured than resulting outputs, which in 
this research is material availability of contingency pharmaceutical items (Hartley and 
Soloman, 2015).  
Therefore a cost-benefit analysis acts as a starting point to, “to identify the costs of 
defense and then ask whether defense provides at least a comparable level of benefits in 
the outputs produced” (Hartley and Soloman, 2015, p. 65). The methodology of this 
research will provide an estimated ratio that attempts to quantify the level of benefits, in 
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the terms of increased material availability, to the economic inputs, in terms of 
programmatic appropriations. 
After monetary values have been established for various impacts to the different 
project sets, uncertainties of the process must be evaluated through sensitivity analysis. 
Utilizing sensitivity analysis allows users to evaluate possible what-if scenarios. 
Identifying possible outcomes can increase confidence in analysis, or help to identify 
areas for further evaluation to refine conclusions bolstered upon the conducted analysis 
(Georgiev, 2015). Sensitivity analysis can be conducted in numerous manners, all ranging 
in complexity and accuracy. The sensitivity analysis methods that will be used in this 
research are partial sensitivity analysis, which looks at how benefits change when a single 
assumption is varied while holding other aspects constant, and maximum and minimum 
case sensitivity analysis, which looks at the impact to benefits when the most or least 
favorable assumptions are applied (Boardman et al., 2011).  
Once sufficient sensitivity analysis has been completed, the analyst can then make a 
recommendation based on the project with the largest present value (Boardman et al., 
2011). It is important to remember that final present values are established from estimates 
of impacts and their resulting monetary values (Boardman et al., 2011). In many 
instances, specifically in the military, there are multiple variables, with different weights, 
that can lead to the selection of one project over another. This means that that completion 
of a cost-benefit analysis is only one input to the entire decision making process. There 
are often other contributing, and sometimes conflicting, factors such as politics, security, 
or legal requirements that can greatly influence final decisions (Boardman et al., 2011). 
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Strategic Sourcing - Centralized Purchasing through Demand Aggregation 
The items that companies or governments procure are purchased to create value as 
a factor in production or meeting organizational requirements (Tate, Fawcett, Schoenherr, 
Ashenbaum, Carter, and Bals, 2016). Given that firms are in most cases required to make 
purchases to assist in their value creation proposition, strategic decisions must be made 
on how purchasing will be conducted throughout the organization. In alignment with the 
theory of transaction cost economics, “Given the considerable volume of resources 
involved, firms and governments always seek to optimize procurement so as to deliver 
value […] In pursuing such a goal often the first important decision is to choose between 
centralized and decentralized purchasing” (Dimitri, Gustavo, and Giancarlo, 2006, p. 47). 
Purchasing from a firm or organization perspective can take various shapes and is a 
strategic decision that must be made to maximize value of the system as a whole.  
The three main purchasing systems include centralized, decentralized, and hybrid 
purchasing models (Dimitri et al., 2006).  In a centralized purchasing model, decisions of 
organizational procurement including determinations of what products to buy, how to 
best navigate procurement channels, and when to make purchases are managed by a 
single entity in the organization (Dimitri et al., 2006). Advantages of centralized 
procurement structures include large scale aggregation of requirements, reductions in 
effort duplication, and more effective supply strategies (Tate et al., 2016).  
In a fully decentralized procurement model, purchases for the organization are 
dispersed amongst different entities, who make more localized decisions of how, what 
and when to make acquisitions (Dimitri, 2006). Although this research supports 
movement away from the full decentralization of purchases, there are inherent benefits to 
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this purchasing structure. Decentralization of purchasing can be more responsive to the 
local units desires and allow for a better understanding of local requirements (Tate et al., 
2016).  The third type of procurement systems are hybrid models. In a hybrid purchasing 
model, purchasing decisions are made both centrally and locally depending on situational 
factors (Dimitri et al., 2006). In this structure, units can either make localized purchases, 
or communicate demand and spending information to a centralized purchasing unit that 
can look for aggregation opportunities leading to better fulfillment and cost savings (Tate 
et al., 2016). 
Before the turn of the century, companies in many cases made strategic decisions 
to give individual business units more independence in terms of purchasing decisions 
(Rozemeijer, van Weele, and Weggeman, 2003). With the shift in increased competition 
in the business environment, these firms are now undergoing consolidation processes in 
their purchasing strategies as they are recognizing the benefits of pooling common 
requirements (Rozemeijer et al., 2003). Organizations are now exhibiting this shift in a 
transition to hybrid purchasing structures with centralized features that leverage sourcing 
benefits of the entire organization’s demand portfolio (Trautmann, Bals, and Hartmann, 
2009).  
A challenge of implementing hybrid practices is clearly defining purchasing 
boundaries and policies. These boundaries involve determining which facets will fall 
under the authority of a centralized purchasing location to maximize organizational wide 
synergies and which facets of the organization will exercise local procurement 
(Trautmann et al., 2009). If organizations are able to overcome the challenges inherent to 
implementing more hybridized purchasing structures, there are numerous benefits. A 
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main benefit of harnessing the capabilities of hybrid purchasing organizations are 
purchasing synergies. Purchasing synergies are defined as resulting value from the 
combination of multiple business units’ resources, information, and knowledge in 
purchasing (Trautmann et al., 2009).  
A relevant example of purchasing synergies currently exhibited in the healthcare 
industry, are Group Purchasing Organizations (GPO). Demand aggregation practices are 
widely applied and utilized in the health care industry through GPOs. A GPO is an 
established entity that healthcare facilities or networks can join to purchase supplies, 
pharmaceuticals, and equipment. Joining the GPO leverages centralized procurement 
benefits, because the GPO consolidates demand from all users and captures the savings 
and efficiency of the larger volume; however, purchases are still made at the hospital or 
health network level under the GPO agreements (Dobson, Heath, Reuter, and DaVanzo, 
2014). There are numerous benefits to procuring healthcare items through a GPO, such as 
greater economies of scale, volume purchasing, increased negotiating power and reduced 
administrative costs (Dobson et al., 2014). The increased economies of scale and volume 
purchasing result from the consolidation of various entities’ demand for like items, which 
ultimately reduces transaction costs.  Due to the benefits of GPOs, it is estimated that 
between 96 and 98 percent of U.S. Hospitals utilize GPO’s in their procurement mix 
(Dobson et al., 2014). 
As discussed previously in the medical contingency procurement process, the Air 
Force primarily obtains items through the DLA established PPV contract. The purchasing 
of required items for each location, based on requirements, is done on a site by site basis 
at the 87 separate stock record account number locations. These accounts do contain a 
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mix of other sub accounts, within their portfolio, however they are still ordered and 
maintained at the main location. For example, Wright Patterson Air Force Base supports 
20 organizations assigned under their account. Of these 20 accounts, 19 are ordered from 
and physically located at Wright Patterson Air Force Base. Contingency items are 
maintained at the primary location and only sent to external locations if required (WPMC 
WRM, 2019). Therefore, this procurement system operates in a decentralized manner, 
with 87 main locations, shown in Appendix C, reporting demand to distributors to obtain 
pharmaceutical items for their site. The research and findings of this research will provide 
justification for the recommendation of transitioning to a model that maintains the local 
sites’ abilities to procure more standard use items through government contracts at their 
own discretion, while harnessing the power of centralized purchasing models through 
demand aggregation to remedy contingency item shortages in the Air Force. 
Relevant Research 
AFMRA/SG4M utilizes an established reporting mechanism, the Air Force 
Shortage Summary Report, to identify and designate the service’s top contingency 
pharmaceutical item shortages. Shortage rankings are designated using an algorithm that 
accounts for the criticality designation of items, individual material availability 
percentages, and assemblage instances with current shortages (JMAR, 2019). 
Initial analysis of these top shortage items, identified on a per item basis in 
Appendix D and site aggregated basis in Figure 2, clearly demonstrated a pattern of 
insufficient site demand profiles correlated with top shortage items. The figure below is 
highly skewed to the left, which signifies the preponderance of insufficient, or small, 
demand signals for identified items, ultimately resulting in shortages.  
Figure 2.  Aggregated Top 20 Contingency Pharmaceutical Items (JMAR, 2019)
Through aggregation of the top ten shortage items, 306 instances of item demand 
were identified. Of the 306 demand instances, 157 (51%) have usage demand profiles of 
less than one item per month. Expanding the pool to the top 20 shortage items shows an 
increasing pattern of 466 demand instances, with 288 occurrences (62%) registering a 
demand of less than one item per month. These sample sets of the program helped 
identify the core issue, insufficient demand signals dispersed across various locations 
leading to instances of shortages, for further analysis. The methodology and results will 
attempt to show how aggregating these small demand profiles will allow the Air Force to 




The theory of transaction cost economics, with its robust theoretical history and 
application in today’s economic environment, is the optimal theory on which to base this 
thesis and resulting cost-benefit analysis. It is clear that although there have been 
programmatic efforts to minimize contingency item shortages that there is still room for 
systematic improvement. The application of strategic sourcing, through leveraging the 
strengths of decentralized and centralized purchasing models, is tried and tested as shown 
by recent business research and findings. 
In the next chapter, the methodology, will describe the avenues and methods for 




The purpose of this chapter is to describe the primary data source and outline the 
construction of the model. The purpose of the model will describe the current situation 
and calculate relevant values such as shortage by location, acquisition costs, and 
transportation costs. The resulting data from the constructed model will then be utilized 
to initiate the cost-benefit analysis of this thesis.  
Data Collection and Model Construction 
The primary data source for this cost-benefit analysis is the Joint Medical Asset 
Repository (JMAR). According to the Defense Health Agency, JMAR is, “a web-enabled 
repository that captures inventory and transactions from distributed medical logistics 
systems at over 400 locations and provides flexible reporting on materiel inventory, 
status, movement and location” (Defense Health Agency, 2018). This data repository 
breaks down contingency medical assets by service component and allows for a thorough 
analysis of the current AFMS Contingency Pharmaceutical Program, with the granularity 
to drill down to individual locations and assemblage component items. Other pertinent 
information was gathered from the Medical Contingency Requirements Workflow 
(MCRW) and AFMRA Medical Requirements List (MRL). Through integrations of raw 
data and generated reports from these platforms, the current state of the AFMS 
Contingency Pharmaceutical Program can be illustrated. The compiled data shows that 
the AD WRM program is made of 2,533 assemblages, 21 percent of which do not meet 
AFMAN 41-209 deployment requirements (JMAR, 2019). These assemblages are 
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programmed for 827K pharmaceutical items to meet demand requirements (JMAR, 
2019). Of these 827K items, there is a shortage of 159K items across 61 locations, 
resulting in a material availability of 80.7 percent. 
After depicting the current pharmaceutical item shortages in the AD WRM portfolio, 
the model for this research was constructed. Pharmaceutical items shortages were 
aggregated based on the item’s prime equivalent (PE) identification number, evaluated 
for PPV contract availability, and lastly assessed for minimum usage thresholds. Upon 
completion of this evaluation there were 646 unique pharmaceutical items that exhibited 
sufficient usage demand upon aggregation (JMAR, 2019). Ultimately, the purpose of this 
model construction is to establish all pertinent information necessary to conduct the costs 
benefit analysis.  
Cost-benefit Analysis Application 
The cost-benefit analysis of this thesis will follow the prescribed steps outlined in 
the literature review. Steps one through three of the cost-benefit analysis fall under the 
methodology portion of this thesis, while steps four through seven will be conducted in 
the subsequent analysis and conclusion sections. 
In the first step of the cost-benefit analysis, four alternative projects were defined. 
The alternative projects to be assessed in this research are: continuation of the status quo, 
centralized purchasing at a single site, centralized purchasing at a single site for U.S. 
regions, and lastly, purchasing at various regional sites. The status quo is included as an 
alternative to act as a benchmark to determine if any resulting action should be taken in 
an attempt to improve the system. Alternative 1 assesses the current situation at sites with 
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AD WRM shortages. In this alternative there will be no proposed changes to 
consolidation of demand and sites will continue to procure items on an individual basis. 
Figure 3.  Alternative 1 Network (DLA Troop Support, 2016) 
Alternative 2 identifies system wide level shortage aggregation opportunities from 
a single designated site to fulfill both U.S. and international site shortages. The site 
selected for this central hub was Kelly Field in San Antonio, Texas. When analyzing 
aggregated demand for each site, Kelly Field had the largest aggregated shortage amount 
of pharmaceutical items (JMAR, 2019).  
Through centralization at Kelly Field, transportation instances would be 
minimized and the current consolidated storage and deployment center (CSDC) mission 
of Kelly Field best suits the demands of receiving, handling, and transporting large 
numbers of contingency medical items (Whitson, 2013). 
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Figure 4.  Alternative 2 Network (DLA Troop Support, 2016) 
Alternative 3 mirrors the strategy and processes of alternative 2, but eliminates 
fulfillment of international region areas in an effort to assess changes in fulfillment and 
transportation costs based on the smaller distribution network. The thought process 
behind this change was that the network could still capture the aggregated demand 
profiles of the sites in the U.S. regions, while eliminating the international shipping costs 
that are required to ship procured items from Kelly Field to various OCONUS locations. 
This process will still identify system wide level shortage aggregation 
opportunities at a single designated site, but only for the U.S. PPV regions of West, 
South, and North. The centralized ordering site for this action will remain at Kelly Field 
for the same justifications outlined in alternative 2. 
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Figure 5.  Alternative 3 Network (DLA Troop Support, 2016) 
Lastly, the fourth alternative identifies global shortage aggregation opportunities 
at regionally designated sites. The sites selected for these regional hubs were designated 
by the Prime Vendor regional delineations of West, South, North, Pacific, and Europe 
(Defense Logistics Agency, 2013). In evaluating aggregated demand, the location with 
largest aggregated shortage amounts for each region were Travis AFB (West), McGuire 
AFB (North), Kelly Field (South), Kadena AB (Pacific), and Ramstein AB (Europe). 
Through centralized purchasing at these locations resulting transportation occurrences 
would be minimized as these ordering locations already have the highest regional demand 
when compared to peers.  
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Figure 6.  Alternative 4 Network (DLA Troop Support, 2016) 
Once alternative projects are fully defined, in the second step of the cost-benefit 
analysis stakeholders need to be identified to ensure no relevant desires and limitations 
are overlooked. Although the identification of stakeholders in this cost-benefit analysis 
will not directly influence the calculated costs, it is important to identify these 
stakeholders from a systems perspective. Starting at the most micro level, the first 
stakeholder would be the local account managing the various assemblages assigned to 
their unit under the MRL. It is important to understand that there will be relatively 
incalculable individual transaction costs at this localized level from the various 
coordination that will take place. This research accounts for these resulting transaction 
costs as fixed costs, as work would be done under the current WRM service contract.  
From the next stakeholder level, the higher headquarters or AFMRA level, these 
local transaction costs may not be realized, but it is important to understand that 
enactment of any of these alternative projects will likely place additional workload on the 
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individual units. At the higher headquarters level, there will need to be communication 
and guidance with the sites conducting the centralized ordering in the form of what items 
are need to be ordered, when orders need to be placed and, when items need to be 
distributed to the demanding locations. 
Following the construction of alternative actions and stakeholder delineation, step 
three of the cost-benefit analysis outlines the costs and benefits of the project. Relevant 
costs to be assessed in this analysis include acquisition costs of procuring shortage items 
and transportation costs of shipping the procured items from the centralized ordering site 
to the demanding site. Acquisition cost as an impact to this cost-benefit analysis will be 
calculated by aggregating the shortage of each item to first determine the amount 
required. Once the shortage amount of each pharmaceutical item is determined, the 
acquisition cost is determined by multiplying the remedied shortage amount by the cost 
per unit established by the PPV contract.  
 Individual item weight information is maintained in the Medical Contingency 
Requirements Workflow (MCRW) portal. Weights, in pound increments, were gathered 
for each of the shortage items to establish a baseline estimate for total weight shipped in 
each alternative project. The average weight of the assessed items was 2.6 pounds, which 
was conservatively rounded up to 3 pounds for shipping cost calculations. Shipping costs 
for three pound shipments were then gathered from third party logistics (3PL) companies 
FedEx and DHL. These 3PL companies are the current Air Force shipping intermediaries 
for contingency pharmaceutical items. Estimated shipping rates used to calculate 
transportation costs were established by gathering shipping quotations for 3 pound 
shipments from Kelly Field to each unique site. From the 60 unique shipping quotations, 
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it was determined that the average domestic shipping cost was $12.02 for a three pound 
shipment and the average international shipping cost was $103.94 for a three pound 
shipment (JMAR, 2019). These values were then proportionally applied to the breakdown 
of anticipated domestic and international shipping amounts, which were 72 percent and 
28 percent of shipments, respectively (JMAR, 2019).  
This resulted in an estimated 3 pound shipping rate of $37.30. This calculation of 
$37.30 per shipment is conservative in nature because shipping costs from the 3PL 
companies are not directly linear when looking at pound increments. This means that a 3 
pound domestic shipment, costing roughly $12.02, would not jump to $24.02 for a 
shipment of 6 pounds. In fact a 6 pound shipment from Kelly Field to Wright Patterson 
AFB, as an example, would only cost $16.64, which less than a 40 percent price increase 
from the shipment containing only 3 pounds. This means that consolidated shipments of 
larger total weights could further optimize total transportation costs.  
The primary benefit to be assessed in this cost-benefit analysis is remedied 
shortage units which will impact the material availability percentage. Shortage units will 
be remedied through the demand aggregation at single and regional ordering sites. The 
remedied shortage amount is finalized by applying a coefficient of .9619, as the average 
fulfillment rate for the contract in FY19 was 96.19 percent. This refinement accounts for 
the fact that although there will be newly generated adequate demand profiles, the 
contract likely will not fulfill 100 percent of the requests.  
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Summary 
This methodology consisting of descriptive data analysis and cost-benefit analysis 
steps of alternative project determination, stakeholder identification and determination of 
impacts quantitatively depicts the current state of AD WRM contingency pharmaceutical 
item shortages. The analysis and results section of this thesis will address the final cost-
benefit analysis steps of impact prediction, monetization and sensitivity analysis. 
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IV. Analysis and Results
Chapter Overview 
The analysis and results section of this thesis will finalize the cost-benefit analysis 
initiated in the methodology section through a theme of predictive analytics by outlining 
cost and benefit predictions, monetization, and sensitivity analysis. Completion of this 
analysis and interpretation of results will set up the final recommendation.  
Analysis and Results 
The results and analysis of this research continues the cost-benefit analysis 
through step four of impact prediction and quantification. Completion of this step 
facilitates the comparison of various alternatives identified earlier in the methodology. 
The below table depicts resulting remedied shortage amounts and shipping weights from 
the various alternatives. 





















Single Site Procurement 
141,607 16,532 258,745 21.3 98.0 
3 
Single Site Procurement 
(U.S. Regions) 




136,210 21,929 247,764 20.4 97.3 
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After impact prediction and quantification is complete, the results are monetized 
for further comparison. The fifth step of monetization in this cost-benefit analysis will 
account for the resulting acquisition and transportation costs, defined earlier, as well as 
monetized values for resulting material availability. The monetary value of increases in 
material availability were established using the principles of the military production 
function, which quantifies militaristic outputs based on monetary inputs (Hartley and 
Soloman, 2015).  
The resulting benefit ratio was calculated using the total AD WRM programmed 
expense of $24.8 million for pharmaceutical procurement. This means that the acquisition 
cost of obtaining full material availability has a value of $24.8M based on contractually 
negotiated pharmaceutical item prices. Therefore, the value of increased material 
availability is calculated to be $248K/percent increase, which was calculated by dividing 
the $24.8M in programmed expenses by total fulfillment. With this estimation, and 
applications of previously discussed monetization of acquisition and transportation costs, 
the final monetization results of the cost-benefit analysis are depicted below. 
Table 2. Cost-benefit Analysis Results with Monetization 









No Change   No Change   No Change   No Change   
2 
Single Site Procurement 
 $ (3,544,601)  $ (1,243,016)  $ 5,287,493  $ 499,875 
3 
Single Site Procurement 
(U.S. Regions) 




 $ (3,033,908)  $ (9,076)  $ 5,085,973  $ 2,042,988 
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It was determined through additional research of the PPV contract that there are 
provisions which covers transportation expenses for intra-region shipping, when orders 
are placed by a Master Ordering Facility (MOF) within the same region (Defense 
Logistics Agency, 2013). This finding was crucial to the estimations and presentations of 
transportation costs, as it would eliminate many transportation expenditures when 
centralized orders are made intra-region.  
Each of the designated ordering hubs, in all alternatives are currently designated 
as Master Ordering Facilities (AFMRA/SG4M, 2019). The decrease in additional 
transportation costs was accounted for South region orders in alternatives 2 and 3, as the 
designated centralized ordering hub of Kelly Field is located in the South Region. Also, 
in alternative 4, the only resulting transportation costs captured in this analysis arise from 
shipment of items from Travis AFB, in the West region, to the Upper Prairie region 
locations. 
After monetization is conducted, the sixth step of sensitivity analysis is completed 
to evaluate uncertainties or what-if scenarios of the alternative options. As these 
pharmaceutical items are procured for uncertain contingency situations, current demand 
could either decrease drastically in instances of contingency draw downs, or increase 
substantially in situations where new conflicts or emergencies arise. The sensitivity 
analysis for this research evaluates shifts in demand through Monte Carlo simulations, 
conducted through the Microsoft Visual Basic Application (VBA). This code was 
constructed to take small scale simulation efforts conducted on a single item to a platform 
such as VBA, which automates the simulations for multiple items simultaneously. The 
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VBA code applied in this research simulates changes in demand patterns for all 1124 
shortage items assessed in this research. Through base case, maximum case, and 
minimum case scenarios validity of the proposed consolidation methods in varying 
situations can be tested. 
In the simulation, a standard deviation of 10 percent (σ = .1) was applied to the 
AD WRM platform’s authorizations for pharmaceutical items to account for possible 
variability in future climates. Shifts in these factors were simulated 10,000 times for each 
item to allow for determining maximum case (ramp up), and minimum case (draw down) 
what-if scenarios. 



















Base Case 824294 136210 21929 247764 20.4 97.3 
Draw Down 
(Min Values) 
506839 68970 30401 148501 16.9 94.0 
Ramp Up 
(Max Values) 
1143028 163723 56488 350084 17.7 95.1 
Average 
(Mode) 
821980 115867 43800 248279 17.4 94.6 
The outcomes this sensitivity analysis, shown here for alternative four, highlights 
that even in instances of varying and uncertain demand, proposed consolidation methods 
could be highly beneficial in terms of improving fulfilment. When looking at resulting 
costs, there is some uncertainty especially in “ramp up” situations. Due to the 
conservative nature of transportation cost estimates used in this research, the calculated 
transportation costs reflect single item shipments with an average weight of three pounds. 
If optimized shipping cost methods were used, for instance by increasing the weight 
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amount of each shipment by sending multiple items in a single shipment, the calculated 
value for transportation cost in each ramp up situation would dramatically decrease and 
make what-if scenarios more attractive in terms of net results. A full outline of the 
simulation results and VBA code are provided in Appendices E and F.  
Summary 
This analysis and results section is bolstered by the fourth, fifth, and sixth steps of 
the cost-benefit analysis process. The fourth step, outlines the resulting impacts being 
assessed in this cost-benefit analysis, which are acquisition costs, transportation costs, 
and material availability. By making the decision to not undertake any demand 
consolidation, the AD WRM program will remain at current material availability levels 
for contingency pharmaceuticals. This cost-benefit analysis suggests that if demand 
aggregation efforts are undertaken that material availability can increase by a range of 
14-21%, depending on which alternative is exercised.
The fifth step of monetization computes the discussed impacts into dollar formats 
to allow aid managerial decisions of selecting projects with positive outcomes. Sensitivity 
analysis, conducted through Monte Carlo simulations accounting for variability in 
demand, shows that these practices of aggregating demand and ordering from a 
centralized or regionalized hub are beneficial, even under significant levels of 
uncertainty. The last step of the cost-benefit analysis process will be addressed in the 
final section of this thesis, the conclusion and recommendation. 
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V. Conclusions and Recommendations
Conclusions of Research 
This research determined that there are strategic supply chain management 
efforts, mainly demand aggregation and centralized procurement, which could be 
employed to mitigate the current AFMS contingency pharmaceutical procurement 
shortfalls. The costs and benefits of these supply chain principles were determined and all 
three proposed alternatives rendered a positive net value. Regardless of decisions made 
on which course of action to undertake, be it a full implementation of one of the 
identified alternatives or a small scale implementation of aggregated purchasing for 
strategically identified items, this research shows the positive effects of practicing 
centralized ordering procedures based on demand aggregation of shortage items.  
Enacting the principles of centralized ordering procedures for shortage items can 
lead to over 20 percent increases in material availability of contingency pharmaceutical 
items. However, as pharmaceuticals are only one subset of the medical contingency item 
platform, this increased availability of pharmaceutical items is only one part of the 
availability issue facing the AFMS in contingency item procurement. To improve the 
material availability of the total AD WRM program, additional efforts will need to be 
taken to diminish shortages in the supply, equipment and repair item areas of the 
program. 
Recommendations for Action 
The final step of the cost-benefit analysis is to provide a final recommendation. 
After determining the flexibility of the PPV contract to utilize Master Ordering Facilities, 
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which can lower intra-region shipping costs, it is recommended to pursue alternative 4 
which advocates for regional procurement hubs across the globe. This alternative has the 
largest net result as it capitalizes on transportation savings, while only experiencing 
minimal decreases to fulfilment levels compared to a single source for procurement of all 
items.  
For instance alternative 4, which evaluates five regional procurement hubs, would 
result in less remedied shortage items than a single procurement site. However, the 
transportation savings resulting from intra-region transportation amount to one million 
dollars. Leaders would have to make the determination if the resulting unfulfilled units 
from alternative 4 is an acceptable shortage when the relevant savings are taken into 
account. The use of the military production function, and assertion that each percent 
increase in material availability renders $248K value, shows that the small difference in 
material availability between alternatives 2 and 4 likely would not be worth the cost of 
the increased transportation expenses resulting from the single ordering and distribution 
point of alternative 2.  
Unless resulting transportation costs of alternative 2 could be drastically 
minimized through optimization of shipping processes, alternative 4 is determined to be 
the optimal solution. Initial concerns in the conduction of this research was that moving 
from a single centralized ordering point to the regional ordering site model would 
drastically diminish the aggregated demand profiles, which would lead to decreased 
fulfillment levels. However, breaking the demands down by region did not have a drastic 
impact on theoretical fulfillment as hypothesized initially. 
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Future Research 
As contingency pharmaceutical items are only one aspect of the AFMS 
contingency item program, future research could be conducted to determine more 
effective ordering policies for those non-pharmaceutical items including contingency 
medical supplies, equipment, and repair items. Completion of this research would provide 
a more robust for necessary actions to fully mitigate all AFMS contingency item 
shortages. Future research could also be addressed at a joint, or Defense Health Agency 
(DHA), level comprised of aggregated Army, Navy and Air Force data. Future shifts in 
military medicine practices, administration, and logistics will see programs moving to a 
more joint service perspective under the DHA. This would undoubtedly result in even 
larger demand signals, which could further improve DoD material availability of 
contingency medical items. 
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Appendicies 
Appendix A. Allowance Standards (“Allowance Standard Management System,” 2019) 
AS Title UTC AS Title UTC AS Title UTC
885A
Med Hospital Surgical 
Expansion Package-Surg 
Equip (HSEP)
FFEES 902V Transport Isolation System IMC FFTS2 915H




Med Hospital Expansion 
Package-Equip Inc 1 (HMEP)
FFEEW 902Y








Med CT Scan Equipment 
Package
FFHAG 902Z Transport Isolation Refit Kit FFTS6 915K




885H Med Ancillary Care Team FFAN1 903A Med Deployable Oxygen Package FF0X2 916E




Med Intensive Care 
Equipment
FFCC1 903B AE Oxygen Support Package FF0X3 916F




Med Radiology Equipment 
Package
FFRA5 903C AE Contingency Support Package FFAM1 917A
Medical Behavioral Health 
Equipment
FFBHE
887A AE Inflight Kits FFQDM 903F Electronic Personal Dosimeters FFPD1 917B
Med Behavioral Health Small 
Equip Package
FFBHS
887B AE Inflight Kit  Resupply FFQDH 903G
Mobile Oxygen Storage Tanks (MOST) 
Package
FFMT1 917C Med Pediatrics Equipment FFPE1
887C
Tactical Critical Care 
Evacuation Team
FFTC1 903K






887D Stacking Litter System FFQD1 903N En Route Care Ex Package FFEC1 917E




Electronic Health Record 
(EHR)
FFEHR 903O
AE Operations Team Augmentation 










Critical Care Air Transport 
Team (CCATT) Adult 
Resupply
FFCCB 903V AES AE Liaison TM Equip Pckg FFQL1 917H
Med Urology Augmentation 
Team  Equipment
FFPP1
887I Stacking Litter Adapters FFQD2 903Y AE Operations Tm Equip Pkg. FFQN1 917I
Med Dental Equipment 
Package
FFF0E
887M Portable Ultra Sound System FFCC5 903Z AE Command Sq Equip Pkg FFQC1 917J




Critical Care Air Transport 
Team (CCATT) Adult 
FFCC4 904E
Deployable Maintenance Equipment 
Package





En Route Patient Staging System 
(ERPSS) 10
FFPS1 917P Med Oral Surgery Equipment FFMA1
887P Patient Movement Items FFQP3 904G
En Route Patient Staging System 
(ERPSS) Equipment PKG - 50 
FFPS2 917Q





Movement Item Tracking 
System (PMITS)
FFQP4 904H
En Route Patient Staging System 
(ERPSS) Expendable PKG - 50
FFPS3 917R
Med EMEDS HA Augmentation 
Tm Equipment
FFP0E
887R Patient Isolation Unit FFP1U 904I
En Route Patient Staging System 
(ERPSS) Facility PKG - 50 Bed 
FFPS4 920A EMERGENCY CRASH CART CCART
893A Blood Donor Center (WHMC) 1FBLD 904J
En Route Patient Staging System 
(ERPSS) Support Package
FFPS7 937N




CONUS Blood Donor Center 
(600 Pint)
2FBLD 904K
En Route Patient Staging System 
(ERPSS) Resupply
FFPS8 938B




Med Expeditionary Blood 
Support Center Equipment
FFLB1 905A Medical Support Package FFSR1 938C




Blood Processing Laboratory 
(ASWBPL)- McGuire
3FBLD 912C
SOF Surgical Primary Response 
Equipment
FFQEF 938D Med EMEDS Basic Resupply FFEE4
893F
Frozen Blood Program 
Equipment
FZNBP 912D
SOF Surgical Electrical Equipment 
Augmentation
FFQEE 938E




Blood Processing Laboratory 
(ASWBPL) - Travis
4FBLD 912G SOF MED Oxygen FFQEU 938F








SOF Base Medical Support - Air Trans 
Treatment Unit (ATTU)
FFQEL 938G







SOF Medical Element Augmentation 
Equipment
FFQEG 938J Med Critical Care Equipment FFEPE
902B
Med BEE NBC Team 
Equipment
FFGL7 912L Casualty Evacuation Module FFQEN 938M





Med Biological Augmentation 
Equipment
FFBA1 912M SOF Surgical Sustainment Equipment FFQES 938P




Med AFRAT-Rad/Nuc Crisis 
ADVON Team
FFRN1 912N
SOF Critical Care Evac Primary 
Response Equipment
FFQEB 938Q Ground Surgical EQ FFGS1
902H
Med AFRAT RAD/NUC 
Surveillance Tm
FFRN2 912O SOF Rapid Response Deployment Kit FFQEM 948A




Med Infectious Disease 
Team Equipment
FFHAF 912Q SOF Critical Care Evac Equipment FFQEC 948E




Med Contagious Casualty 
Management - CCM
FFCCM 912R
SOF Extended Reach Medical 
Equipment
FFQED 948F




Med AFRAT RAD/NUC 
Surveillance Aug Equipment
FFRND 912S SOF PEDS FFQEJ 948G




Med AFRAT RAD/NUC 
Laboratory Team
FFRN4 912W SOF Irregular Warfare FFQEW 948H




Med AFRAT RAD/NUC 
Laboratory Aug Equipment
FFRNB 913J Pararescue Medical Support Kits 81SBD 948I




Med AFRAT RAD/NUC 
Dosimetry Team
FFRN6 913K
Pararescue Medical Support Accessory 
Kits
81SLG 948J MED CP 3 TENT W/AIRLOCK FFCP3
902P
Med AFRAT RAD/NUC 
Dosimetry Aug Equipment
FFRNC 913N NASA Assemblage NASA1 948K MED CP 3 TENT CPEL FFCP4
902U
Transport Isolation System 
(TIS ) AM and IME
FFTS1 915G Medical Global Reach Laydown Team FFGR1 948L MED CP ONE TENT FFCP5
Allowance Standard List
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